.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

ZINGO Drug Profile

« Back to Dashboard
Zingo is a drug marketed by Powder Pharms and is included in one NDA. It is available from three suppliers. There are six patents protecting this drug.

This drug has seventy-two patent family members in thirty-four countries.

The generic ingredient in ZINGO is lidocaine hydrochloride. There are twenty-nine drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the lidocaine hydrochloride profile page.

Summary for Tradename: ZINGO

Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Drug Prices: :see details

Pharmacology for Tradename: ZINGO

Ingredient-typeAmides
Drug ClassAmide Local Anesthetic
Antiarrhythmic
Physiological EffectLocal Anesthesia
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Powder Pharms
ZINGO
lidocaine hydrochloride
SYSTEM;INTRADERMAL022114-001Aug 16, 2007RXNo8,540,665► subscribe ► subscribe
Powder Pharms
ZINGO
lidocaine hydrochloride
SYSTEM;INTRADERMAL022114-001Aug 16, 2007RXNo6,881,200► subscribeY ► subscribe
Powder Pharms
ZINGO
lidocaine hydrochloride
SYSTEM;INTRADERMAL022114-001Aug 16, 2007RXNo9,358,338► subscribe ► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZINGO

These historical archives are available as an add-on to one-year subscriptions.
See the Subscription Options for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Powder Pharms
ZINGO
lidocaine hydrochloride
SYSTEM;INTRADERMAL022114-001Aug 16, 20075,899,880► subscribe
Powder Pharms
ZINGO
lidocaine hydrochloride
SYSTEM;INTRADERMAL022114-001Aug 16, 20076,881,200► subscribe
Powder Pharms
ZINGO
lidocaine hydrochloride
SYSTEM;INTRADERMAL022114-001Aug 16, 20075,630,796► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ZINGO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,630,796 Method of delivering powder transdermally with needless injector► subscribe
9,044,546Particle cassettes and processes therefor► subscribe
7,942,846Needleless syringe using supersonic gas flow for particle delivery► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ZINGO

Country Document Number Estimated Expiration
European Patent Office0951917► subscribe
United Kingdom9307459► subscribe
China1120852► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc